Cross-border freight forwarding and customs brokerage
Strategic Profile
Through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.—Lakeside delivers tailored logistics solutions spanning general and specialized sectors. Its customers are typically Asia- and U.S.-based logistics service companies serving large e-commerce platforms, social commerce platforms, and manufacturers to sell and transport consumer and industrial goods made in Asia into the U.S.
Cyborg Score Rationale
The company's established cross-border freight solutions experienced revenue declines compared to the prior year, primarily due to shifts in global shipping demands. However, diversification into pharmaceutical logistics and recent financing activity signal strategic adaptation in a challenging operating environment.
Top Insights
Operates dual specialized subsidiaries targeting logistics and pharmaceutical sectors in Asia-Pacific trade flows
(March 2025) Announced $4.5M convertible debt financing with 40% warrant coverage to support working capital and growth initiatives
(June 2024) IPO raised $6.75M at $4.50/share, enabling expansion of cross-border capabilities and customer acquisition
Experienced revenue pressure in fiscal 2025 Q3 (ended March 2025) despite strategic focus on high-margin pharmaceutical logistics through Hupan subsidiary
Named Competitors
DHL Global Forwarding — Major global freight forwarder and logistics provider
FedEx International — Global logistics and express delivery services
Flexport — Digital freight forwarding and customs brokerage platform
C.H. Robinson — Third-party logistics and freight services
Recent Developments
(May 2025) Announced Q3 fiscal 2025 results showing revenue challenges in established cross-border freight amid global shipping demand shifts
(March 2025) Announced $4.5M convertible debt financing with institutional investor to support working capital
(December 2024) Signed $1.5M sales agreement with Sinopharm Group subsidiary for pharmaceutical logistics
(November 2024) Strengthened market position in China's pharmaceutical logistics with Sinopharm (Hubei) contracts
Open the full interactive Lakeside Holding Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.